Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

213 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Hyperprogressive Disease in Patients With Advanced Non-Small Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or With Single-Agent Chemotherapy.
Ferrara R, Mezquita L, Texier M, Lahmar J, Audigier-Valette C, Tessonnier L, Mazieres J, Zalcman G, Brosseau S, Le Moulec S, Leroy L, Duchemann B, Lefebvre C, Veillon R, Westeel V, Koscielny S, Champiat S, Ferté C, Planchard D, Remon J, Boucher ME, Gazzah A, Adam J, Bria E, Tortora G, Soria JC, Besse B, Caramella C. Ferrara R, et al. Among authors: koscielny s. JAMA Oncol. 2018 Nov 1;4(11):1543-1552. doi: 10.1001/jamaoncol.2018.3676. JAMA Oncol. 2018. PMID: 30193240 Free PMC article.
Comparison of Fast-Progression, Hyperprogressive Disease, and Early Deaths in Advanced Non-Small-Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or Chemotherapy.
Ferrara R, Mezquita L, Texier M, Lahmar J, Audigier-Valette C, Tessonnier L, Mazieres J, Zalcman G, Brosseau S, Le Moulec S, Leroy L, Duchemann B, Lefebvre C, Veillon R, Westeel V, Koscielny S, Champiat S, Ferté C, Planchard D, Remon J, Boucher ME, Gazzah A, Adam J, Lo Russo G, Signorelli D, Garassino MC, Soria JC, Caramella C, Besse B. Ferrara R, et al. Among authors: koscielny s. JCO Precis Oncol. 2020 Nov;4:829-840. doi: 10.1200/PO.20.00021. JCO Precis Oncol. 2020. PMID: 35050757
TGR analysis in phase I clinical trials--response.
Ferté C, Koscielny S, Soria JC. Ferté C, et al. Among authors: koscielny s. Clin Cancer Res. 2014 May 1;20(9):2497. doi: 10.1158/1078-0432.CCR-14-0366. Clin Cancer Res. 2014. PMID: 24789036 No abstract available.
Tumor growth rate provides useful information to evaluate sorafenib and everolimus treatment in metastatic renal cell carcinoma patients: an integrated analysis of the TARGET and RECORD phase 3 trial data.
Ferté C, Koscielny S, Albiges L, Rocher L, Soria JC, Iacovelli R, Loriot Y, Fizazi K, Escudier B. Ferté C, et al. Among authors: koscielny s. Eur Urol. 2014 Apr;65(4):713-20. doi: 10.1016/j.eururo.2013.08.010. Epub 2013 Aug 15. Eur Urol. 2014. PMID: 23993162 Clinical Trial.
Tumour growth rates and RECIST criteria in early drug development.
Gomez-Roca C, Koscielny S, Ribrag V, Dromain C, Marzouk I, Bidault F, Bahleda R, Ferté C, Massard C, Soria JC. Gomez-Roca C, et al. Among authors: koscielny s. Eur J Cancer. 2011 Nov;47(17):2512-6. doi: 10.1016/j.ejca.2011.06.012. Epub 2011 Jul 15. Eur J Cancer. 2011. PMID: 21763126
A simplified interventional mapping system (SIMS) for the selection of combinations of targeted treatments in non-small cell lung cancer.
Lazar V, Rubin E, Depil S, Pawitan Y, Martini JF, Gomez-Navarro J, Yver A, Kan Z, Dry JR, Kehren J, Validire P, Rodon J, Vielh P, Ducreux M, Galbraith S, Lehnert M, Onn A, Berger R, Pierotti MA, Porgador A, Pramesh CS, Ye DW, Carvalho AL, Batist G, Le Chevalier T, Morice P, Besse B, Vassal G, Mortlock A, Hansson J, Berindan-Neagoe I, Dann R, Haspel J, Irimie A, Laderman S, Nechushtan H, Al Omari AS, Haywood T, Bresson C, Soo KC, Osman I, Mata H, Lee JJ, Jhaveri K, Meurice G, Palmer G, Lacroix L, Koscielny S, Eterovic KA, Blay JY, Buller R, Eggermont A, Schilsky RL, Mendelsohn J, Soria JC, Rothenberg M, Scoazec JY, Hong WK, Kurzrock R. Lazar V, et al. Among authors: koscielny s. Oncotarget. 2015 Jun 10;6(16):14139-52. doi: 10.18632/oncotarget.3741. Oncotarget. 2015. PMID: 25944621 Free PMC article.
Tumor assessment criteria in phase I trials: beyond RECIST.
Levy A, Hollebecque A, Ferté C, Koscielny S, Fernandez M, Soria JC, Massard C. Levy A, et al. Among authors: koscielny s. J Clin Oncol. 2013 Jan 20;31(3):395. doi: 10.1200/JCO.2012.46.2184. Epub 2012 Dec 17. J Clin Oncol. 2013. PMID: 23248247 No abstract available.
213 results